尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白
Recombinant Plasminogen Activator, Urokinase Receptor (uPAR)
CD87; PLAUR; PLAU-R; U-PAR; URKR; Monocyte Activation Antigen Mo3
- 編號(hào)URPA141Mu02
- 物種Mus musculus (Mouse，小鼠) 相同的名稱，不同的物種。
- 來(lái)源原核表達(dá)
- 宿主E.coli
- 內(nèi)毒素水平<1.0EU/µg(LAL法測(cè)定)
- 亞細(xì)胞定位n/a
- 預(yù)測(cè)分子量-
- 實(shí)際分子量-(差異分析請(qǐng)參閱說(shuō)明書(shū))
- 片段與標(biāo)簽N-terminal His Tag
- 緩沖液成份磷酸鹽緩沖液（pH7.4，含有 0.01% SKL, 1mM DTT, 5% Trehalose和Proclin300.）
- 性狀凍干粉
- 純度> 97%
- 等電點(diǎn)-
-
應(yīng)用
Positive Control; Immunogen; SDS-PAGE; WB.
如果需要有生物活性的蛋白，請(qǐng)參見(jiàn)活性蛋白。 - 下載 英文說(shuō)明書(shū) 中文說(shuō)明書(shū)
- 規(guī)格 10μg50μg 200μg 1mg 5mg
- 價(jià)格 ¥ 360 ¥ 900 ¥ 1800 ¥ 5400 ¥ 13500
- 欲了解實(shí)際交易價(jià)格和更多情況，請(qǐng)與當(dāng)?shù)亟?jīng)銷商聯(lián)系!
-
產(chǎn)品包裝(模擬)
-
產(chǎn)品包裝(模擬)
-
通過(guò)ISO 9001、ISO 13485質(zhì)量體系認(rèn)證
序列
用法
PBS或其它。
儲(chǔ)存
避免反復(fù)凍融。2-8°C不超過(guò)一個(gè)月，-80°C不超過(guò)12個(gè)月。
穩(wěn)定性
熱穩(wěn)定性以損失率顯示。損失率是由加速降解試驗(yàn)決定，具體方法如下：在37°C孵育48小時(shí)，沒(méi)有顯著的降解或者沉淀產(chǎn)生。保質(zhì)期內(nèi)，在適當(dāng)?shù)臈l件下存儲(chǔ)，損失率低于5%。
贈(zèng)品
增值服務(wù)
相關(guān)產(chǎn)品
| 編號(hào) | 適用物種：Mus musculus (Mouse，小鼠) | 應(yīng)用(僅供研究使用，不用于臨床診斷！) |
| URPA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UAPA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)活性蛋白 | Cell?culture;?Activity?Assays. |
| URPA141Mu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)重組蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
| UPAA141Mu01 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB |
| UPAA141Mu02 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體 | WB; IHC; ICC; IP. |
| ULAA141Mu71 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(生物素標(biāo)記) | WB |
| ULAA141Mu81 | 尿激酶型纖溶酶原激活因子受體(uPAR)多克隆抗體(異硫氰酸熒光素標(biāo)記) | WB; IHC; ICC; IF. |
| USEA141Mu | 尿激酶型纖溶酶原激活因子受體(uPAR)檢測(cè)試劑盒(酶聯(lián)免疫吸附試驗(yàn)法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
| ULMA141Mu | 尿激酶型纖溶酶原激活因子受體(uPAR)等多因子檢測(cè)試劑盒(流式熒光發(fā)光法) | FLIA Kit for Antigen Detection. |
參考文獻(xiàn)
| 雜志 | 參考文獻(xiàn) |
| International Journal of Cancer | Dietary supplementation with methylseleninic acid, but not selenomethionine, reduces spontaneous metastasis of Lewis lung carcinoma in mice [Wiley: source] |
| Biomark Insights | Decreased Epidermal Growth Factor (EGF) Associated with HMGB1 and Increased Hyperactivity in Children with Autism [PubMed: PMC3623607] |
| Biomarker insights | Decreased Hepatocyte Growth Factor (HGF) and Gamma Aminobutyric Acid (GABA) in Individuals with Obsessive-Compulsive Disorder (OCD) [PubMed: PMC3762604] |
| Am J Emerg Med | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic guidance of sepsis [PubMed: 26615223] |
| Archives of Clinical Infectious Diseases | Evaluation of Diagnostic Value of Soluble Urokinase-Type Plasminogen Activator Receptor in Sepsis [Archcid: 26346] |
| The American Journal of Emergency Medicine | Clinical value of soluble urokinase-type plasminogen activator receptor in the diagnosis, prognosis, and therapeutic Cavia (Guinea pig )idance of sepsis [science:S0735675715009559] |
| Journal of Clinical and Experimental Hepatology | Evaluation of Plasma Urokinase-Type Plasminogen Activator Receptor (UPAR) in Patients With Chronic Hepatitis B, C and Non-Alcoholic Fatty Liver Disease (NAFLD)?… [10.1016:j.jceh.2018.02.001] |
| Turkish journal of trauma & emergency surgery | The diagnostic value of serum urokinase-type plasminogen activator receptor in acute appendicitis [Pubmed: 31475329] |
| CELL TRANSPLANTATION | Predictive Value of Degranulating Factors of Neutrophils in Massive Cerebral Infarction [33787356] |
留言咨詢
